Author: Benzinga Newsdesk | August 12, 2025 05:03pm
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.19) by 36.84 percent. This is a 52.94 percent decrease over losses of $(0.17) per share from the same period last year.